Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Cellarity, a life sciences company, has announced several key leadership appointments to enhance its innovative drug discovery platform. John Leaman, M.D., M.B.A., joins as Chief Financial Officer, bringing extensive experience from Impel Pharmaceuticals, Selecta Biosciences, and Medgenics. Cameron Trenor, M.D., is appointed as Vice President and Head of Translational Medicine, with a strong background in hematology drug development. Anjali Kumar, Ph.D., takes on the role of Vice President, Head of Business Development, previously leading innovation at Johnson & Johnson. Additionally, Parul Doshi, M.B.A., has been promoted to Chief Data Officer. These changes aim to accelerate Cellarity's progress towards its clinical pipeline, leveraging its proprietary AI platform to create novel drug candidates for complex diseases.
On March 21, 2023, Selecta Biosciences (NASDAQ: SELB) reported positive topline results from its Phase 3 DISSOLVE I and II trials for SEL-212, an investigational treatment for chronic refractory gout. In DISSOLVE I, 56% of patients achieved a response at a high dose, significantly outperforming the placebo rate of 4%. DISSOLVE II showed a 47% response rate at the same dosage compared to 12% for placebo. The treatment demonstrated a 69% reduction in serum urate levels and maintained a favorable safety profile, with only 3.4% of patients experiencing infusion reactions. The company aims to file for U.S. marketing approval in the first half of 2024.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
